NKGen Biotech, Inc.

OTC: NKGN · Healthcare · Biotechnology

PublicHQ Santa Ana, CA · OrangeCIK 0001845459Reports USD

#1163 of 1,418 Healthcare companies by revenuebottom-decile growth

EA Score

——

FH —DQ 1GM —SS 28

v0.1 · 25/100 weight · pillars only

↑ Piotroski F, workforce scale · ↓ revenue growth (YoY), disclosure history

Methodology →

Revenue TTM

$652.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$44.3M

Employees

as of 2026-09-21

Market cap

$261.2k

as of 2026-09-21

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02023

Net income-$44.3M-$44.3M2024

Operating income-$27.0M-$27.0M2024

Total assets$16.2M$16.2M2024

Liabilities$86.1M$86.1M2024

Equity-$69.9M-$69.9M2024

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is NKGen Biotech, Inc.’s revenue?

NKGen Biotech, Inc. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Biocure Technology Inc.——Bakhu Holdings, Corp.——Burzynski Research Institute, Inc.——EGF Theramed Health Corp.——Marijuana Inc.——eWellness Healthcare Corp.——

Neighbors

Orange →

Edwards Lifesciences Corporation$6.1B86A Chipotle Mexican Grill, Inc.$11.9B76B+Rivian Automotive, Inc.$5.4B37D TTM Technologies, Inc.$2.9B73B American Healthcare REIT, Inc.$2.1B57C Skyworks Solutions, Inc.$4.1B78B+

Key facts

CEOPaul Y. Song

SectorHealthcare

IndustryBiotechnology

HeadquartersSanta Ana, CA

ExchangeOTC: NKGN

Employees26

IPO date2021-07-13

Latest filings

8-K2026-09-02 8-K2026-07-17 8-K2026-06-02 8-K2026-05-21 8-K2026-05-04 8-K2026-04-21 8-K2026-02-26 8-K2026-02-05

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.